BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 20232018)

  • 1. [Nonantimicrobial effects of tetracyclines].
    GarcĂ­a-Alvarez L; Oteo JA
    Rev Esp Quimioter; 2010 Mar; 23(1):4-11. PubMed ID: 20232018
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chemically modified tetracyclines as inhibitors of matrix metalloproteinases.
    Acharya MR; Venitz J; Figg WD; Sparreboom A
    Drug Resist Updat; 2004 Jun; 7(3):195-208. PubMed ID: 15296861
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Matrix metalloproteinase inhibitor properties of tetracyclines: therapeutic potential in cardiovascular diseases.
    Castro MM; Kandasamy AD; Youssef N; Schulz R
    Pharmacol Res; 2011 Dec; 64(6):551-60. PubMed ID: 21689755
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tetracyclines: nonantibiotic properties and their clinical implications.
    Sapadin AN; Fleischmajer R
    J Am Acad Dermatol; 2006 Feb; 54(2):258-65. PubMed ID: 16443056
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of tetracycline as an inhibitor of matrix metalloproteinase activity secreted by human bone-metastasizing cancer cells.
    Duivenvoorden WC; Hirte HW; Singh G
    Invasion Metastasis; 1997; 17(6):312-22. PubMed ID: 9949290
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Non-antimicrobial properties of tetracyclines--dental and medical implications.
    Rawal SY; Rawal YB
    West Indian Med J; 2001 Jun; 50(2):105-8. PubMed ID: 11677904
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synthesis and in vitro evaluation of targeted tetracycline derivatives: effects on inhibition of matrix metalloproteinases.
    Vidal A; Sabatini M; Rolland-Valognes G; Renard P; Madelmont JC; Mounetou E
    Bioorg Med Chem; 2007 Mar; 15(6):2368-74. PubMed ID: 17267227
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Potential application of a chemically modified non-antimicrobial tetracycline (CMT-3) against metastatic prostate cancer.
    Lokeshwar BL; Houston-Clark HL; Selzer MG; Block NL; Golub LM
    Adv Dent Res; 1998 Nov; 12(2):97-102. PubMed ID: 9972130
    [No Abstract]   [Full Text] [Related]  

  • 9. [Doxycycline or how to create new with the old?].
    Shehwaro N; Langlois AL; Gueutin V; Gauthier M; Casenave M; Izzedine H
    Therapie; 2014; 69(2):129-41. PubMed ID: 24926631
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tetracyclines inhibit connective tissue breakdown by multiple non-antimicrobial mechanisms.
    Golub LM; Lee HM; Ryan ME; Giannobile WV; Payne J; Sorsa T
    Adv Dent Res; 1998 Nov; 12(2):12-26. PubMed ID: 9972117
    [TBL] [Abstract][Full Text] [Related]  

  • 11. How do tetracyclines work?
    Ryan ME; Ashley RA
    Adv Dent Res; 1998 Nov; 12(2):149-51. PubMed ID: 9972140
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An update on tetracyclines.
    Shlaes DM
    Curr Opin Investig Drugs; 2006 Feb; 7(2):167-71. PubMed ID: 16499287
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Matrix metalloproteinases (MMPs) and tissue inhibitors of MMPs in the respiratory tract: potential implications in asthma and other lung diseases.
    Gueders MM; Foidart JM; Noel A; Cataldo DD
    Eur J Pharmacol; 2006 Mar; 533(1-3):133-44. PubMed ID: 16487964
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antimicrobial and non-antimicrobial tetracyclines in human cancer trials.
    Richards C; Pantanowitz L; Dezube BJ
    Pharmacol Res; 2011 Feb; 63(2):151-6. PubMed ID: 20951804
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Metalloproteinases in tumor progression. Review].
    Arvelo F; Cotte C
    Invest Clin; 2006 Jun; 47(2):185-205. PubMed ID: 16886780
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A new face for old antibiotics: tetracyclines in treatment of amyloidoses.
    Stoilova T; Colombo L; Forloni G; Tagliavini F; Salmona M
    J Med Chem; 2013 Aug; 56(15):5987-6006. PubMed ID: 23611039
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The nonantimicrobial properties of tetracycline for the treatment of periodontal disease.
    Vernillo AT; Ramamurthy NS; Golub LM; Rifkin BR
    Curr Opin Periodontol; 1994; ():111-8. PubMed ID: 8032451
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CMT-3. CollaGenex.
    Fingleton B
    Curr Opin Investig Drugs; 2003 Dec; 4(12):1460-7. PubMed ID: 14763133
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Matrix metalloproteinases and their inhibition in periodontal treatment.
    Ryan ME; Ramamurthy S; Golub LM
    Curr Opin Periodontol; 1996; 3():85-96. PubMed ID: 8624573
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical applications of non-antimicrobial tetracyclines in dermatology.
    Monk E; Shalita A; Siegel DM
    Pharmacol Res; 2011 Feb; 63(2):130-45. PubMed ID: 20937386
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.